You are here: Industry Insights > INOVIO

News List

Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial drugs
May 22, 2019
Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial.
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor en-cphi.cn
April 03, 2019
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) has completed its enrollment three months ahead of schedule.
Inovio announces demonstration of 100% immunogenicity of its Ebola Vaccine biospectrumasia
March 25, 2019
The Phase 1 data was published in The Journal of Infectious Diseases and further supports……
Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer en-cphi.cn
March 07, 2019
The second Phase 3 study initiation announcement made during the International HPV Awareness Day
Inovio’s Synthetic DNA Vaccine Shows Promise in Treating HPV-Related Head & Neck Cancer americanpharmaceuticalreview
January 25, 2019
Inovio Pharmaceuticals announced a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved ....
First clinical MERS vaccine by Inovio and GeneOne shows promise fiercevaccines
July 23, 2018
Inovio and GeneOne Life Science’s MERS vaccine, which is receiving financial support from the International Vaccine Institute (IVI) and the Coalition for Epidemic Preparedness Innovations (CEPI), elicited high levels of antibodies and T-cell responses in
First clinical MERS vaccine by Inovio and GeneOne shows promise fiercevaccines
July 10, 2018
Inovio and GeneOne Life Science’s MERS vaccine, which is receiving financial support from the International Vaccine Institute (IVI) and the Coalition for Epidemic Preparedness Innovations (CEPI), elicited high levels of antibodies and T-cell responses in
Inovio nets $56M CEPI grant for Lassa fever and MERS vaccines fiercepharma
April 16, 2018
The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.
With $7M NIH grant, Inovio set to test HIV vaccine with a checkpoint inhibitor fiercepharma
April 06, 2017
After successfully shepherding a Zika vaccine candidate into the clinic before any other developer, Inovio Pharmaceuticals is amping up its efforts in HIV.

Previous page 1 2 3 4 5 Next page